<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05063344</url>
  </required_header>
  <id_info>
    <org_study_id>NOWDx Syphilis Study</org_study_id>
    <nct_id>NCT05063344</nct_id>
  </id_info>
  <brief_title>NOWDx Test for the Diagnosis of Syphilis</brief_title>
  <official_title>NOWDx Test for the Diagnosis of Syphilis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOWDiagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOWDiagnostics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the performance of the NOWDx Syphilis Test to a currently&#xD;
      marketed device. The intent is to show the rapid test device is comparable to the currently&#xD;
      marketed device. The NOWDx Syphilis Test is intended for qualitatively detecting the presence&#xD;
      or absence of human antibodies to syphilis in human whole blood to aid in the diagnosis of&#xD;
      infection caused by Treponema pallidum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to establish the performance characteristics of the NOWDx&#xD;
      Syphilis Test based on comparison to the BioRad Bioplex 2200 series Syphilis Total (IgG/IgM),&#xD;
      Wampole Impact RPR Test Kit, and to the Serodia Treponema pallidum particle agglutination&#xD;
      assay (TP-PA).&#xD;
&#xD;
      The external clinical study along with in-house analytical studies will demonstrate the&#xD;
      efficacy of the NOWDx Syphilis Test as an aid in the diagnosis of syphilis infection for at&#xD;
      home testing and point of care testing sites. Participants will self test and be tested by&#xD;
      Clinical Laboratory Improvement Amendments (CLIA) Waived operators with the NOWDx Syphilis&#xD;
      Test at independent sites in WA, AZ, and NV. Two sample types will be tested with the NOWDx&#xD;
      Syphilis Test for each participant: fingerstick whole blood and venous whole blood. Sera from&#xD;
      each participant will be tested at an independent reference laboratory.&#xD;
&#xD;
      The NOWDx Syphilis Test will be evaluated in diverse populations of sexually active persons&#xD;
      who self-select for syphilis testing and expectant mothers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare serological status to comparator method</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>The comparator method used in this study is an algorithm comprised of results from three different commercially available syphilis assays: an FDA-cleared treponemal immunoassay, an FDA-cleared non-treponemal assay (RPR assay) and a second treponemal assay (TP-PA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate test reproducibility by lay users</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Test lay user reproducibility using prepared samples for % agreement with expected results.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1140</enrollment>
  <condition>Syphilis Infection</condition>
  <condition>Treponema Pallidum Infection</condition>
  <arm_group>
    <arm_group_label>Sexually active persons who self-select for syphilis testing</arm_group_label>
    <description>Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expectant mothers</arm_group_label>
    <description>Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lay users</arm_group_label>
    <description>Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diagnostic Test: NOWDx Syphilis Test</intervention_name>
    <description>For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.</description>
    <arm_group_label>Expectant mothers</arm_group_label>
    <arm_group_label>Lay users</arm_group_label>
    <arm_group_label>Sexually active persons who self-select for syphilis testing</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of the U.S. who elect to participate in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Sexually active persons who self-select for syphilis testing&#xD;
&#xD;
               -  n=840 participants; ~280 per study site&#xD;
&#xD;
               -  Inclusion criteria:&#xD;
&#xD;
                  - sexually active persons 18-64 years old&#xD;
&#xD;
               -  Exclusion criteria:&#xD;
&#xD;
                    -  persons &lt;18 years old; persons &gt;64 years old;&#xD;
&#xD;
                    -  persons with limited or no reading skills;&#xD;
&#xD;
                    -  persons who previously participated in a NOWDx study&#xD;
&#xD;
          -  Expectant mothers&#xD;
&#xD;
               -  n=222 participants; ~74 per study site&#xD;
&#xD;
               -  Inclusion criteria:&#xD;
&#xD;
                  - expectant mothers ≥18 years old&#xD;
&#xD;
               -  Exclusion criteria:&#xD;
&#xD;
                    -  persons &lt;18 years old;&#xD;
&#xD;
                    -  persons with limited or no reading skills;&#xD;
&#xD;
                    -  persons who previously participated in a NOWDx study&#xD;
&#xD;
          -  Lay users&#xD;
&#xD;
               -  n=48 participants; ~16 per study site&#xD;
&#xD;
               -  Inclusion criteria:&#xD;
&#xD;
                    -  persons 18-64 years old;&#xD;
&#xD;
                    -  -½ high risk sexual behavior; ½ low risk sexual behavior&#xD;
&#xD;
               -  Exclusion criteria:&#xD;
&#xD;
                    -  persons &lt;18 years old; persons &gt;64 years old;&#xD;
&#xD;
                    -  persons with limited or no reading skills;&#xD;
&#xD;
                    -  persons who previously participated in a NOWDx study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Beth Cobb</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOW Diagnostics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Cobb</last_name>
    <phone>479-966-4531</phone>
    <email>beth.cobb@nowdx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelsi Thurman</last_name>
    <phone>479-966-4529</phone>
    <email>kelsi.thurman@nowdx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMR Tempe</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corey Anderson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jacobs, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicare Rockwood</name>
      <address>
        <city>Cheney</city>
        <state>Washington</state>
        <zip>99004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Staben, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Syphilis</keyword>
  <keyword>Treponema Pallidum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

